--- schema_version: "secwatch.filing_event.v1" accession: "0001140361-22-022218" form_type: "8-K" ticker: "ERNA" cik: "0000748592" company_name: "Ernexa Therapeutics Inc." filed_at: "2022-06-07T23:59:59+00:00" generated_at: "2026-06-25T04:07:04.919216+00:00" event_type: "leadership" sentiment: "neutral" materiality_score: 0.65 calibrated_materiality_score: 0.65 confidence: "high" source: SEC EDGAR --- # Brooklyn ImmunoTherapeutics replaces four directors; appoints Angel, Fiore, Wexler, Singer ## Summary - Four directors (Langer, Mohr, Enright, Redman) resigned effective June 5, 2022; no disagreement cited. - Board size reduced from six to five; then appointed four new directors to fill vacancies. - Appointees include Matthew Angel (interim CEO), Gregory Fiore (CEO of Exacis), William Wexler (restructuring expert), Nicholas Singer (founder of Purchase Capital). - Wexler and Singer deemed independent; Singer qualifies as audit committee financial expert. - No material transactions with new directors except prior rights offering participation by Singer ($1.29M) and Angel's prior appointment. ## SEC filing metadata - accession: 0001140361-22-022218 - form_type: 8-K - ticker: ERNA - cik: 0000748592 - company_name: Ernexa Therapeutics Inc. - filed_at: 2022-06-07T23:59:59+00:00 - event_type: leadership - sentiment: neutral - materiality_score: 0.65 - calibrated_materiality_score: 0.65 - confidence: high - sec_items: 5.02 - EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036122022218/0001140361-22-022218-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036122022218/brhc10038551_form8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001140361-22-022218 - JSON: https://secwatch.observer/filing/0001140361-22-022218.json - Plain text: https://secwatch.observer/filing/0001140361-22-022218.txt ## Key facts - Executive change Gregory Fiore was appointed as Director at Ernexa Therapeutics Inc.. - Action: appointed - Role: Director source text: On June 5, 2022, the Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby. evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122022218/0001140361-22-022218-index.htm - Executive change Erich Mohr resigned as Director at Ernexa Therapeutics Inc.. - Action: resigned - Role: Director source text: On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board, as described below. evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122022218/0001140361-22-022218-index.htm - Executive change William Wexler was appointed as Director at Ernexa Therapeutics Inc.. - Action: appointed - Role: Director source text: On June 5, 2022, the Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby. evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122022218/0001140361-22-022218-index.htm - Executive change Dennis Langer resigned as Director at Ernexa Therapeutics Inc.. - Action: resigned - Role: Director source text: On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board, as described below. evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122022218/0001140361-22-022218-index.htm - Executive change Matthew Angel was appointed as Director at Ernexa Therapeutics Inc.. - Action: appointed - Role: Director source text: On June 5, 2022, the Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby. evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122022218/0001140361-22-022218-index.htm - Executive change Nicholas Singer was appointed as Director at Ernexa Therapeutics Inc.. - Action: appointed - Role: Director source text: On June 5, 2022, the Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby. evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122022218/0001140361-22-022218-index.htm - Executive change Erin Enright resigned as Director at Ernexa Therapeutics Inc.. - Action: resigned - Role: Director source text: On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board, as described below. evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122022218/0001140361-22-022218-index.htm - Executive change Heather Redman resigned as Director at Ernexa Therapeutics Inc.. - Action: resigned - Role: Director source text: On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board, as described below. evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036122022218/0001140361-22-022218-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.